

Oral Solid Dosage Pharmaceutical Formulation- Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/O8C502D617FMEN.html>

Date: February 2018

Pages: 142

Price: US\$ 3,480.00 (Single User License)

ID: O8C502D617FMEN

Abstracts

Report Summary

Oral Solid Dosage Pharmaceutical Formulation-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Oral Solid Dosage Pharmaceutical Formulation industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Oral Solid Dosage Pharmaceutical Formulation 2013-2017, and development forecast 2018-2023

Main market players of Oral Solid Dosage Pharmaceutical Formulation in Europe, with company and product introduction, position in the Oral Solid Dosage Pharmaceutical Formulation market

Market status and development trend of Oral Solid Dosage Pharmaceutical Formulation by types and applications

Cost and profit status of Oral Solid Dosage Pharmaceutical Formulation, and marketing status

Market growth drivers and challenges

The report segments the Europe Oral Solid Dosage Pharmaceutical Formulation market as:

Europe Oral Solid Dosage Pharmaceutical Formulation Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany
United Kingdom
France
Italy
Spain
Benelux
Russia

Europe Oral Solid Dosage Pharmaceutical Formulation Market: Product Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

By Form
Capsules
Powders
Tablets
By Drug Release Mechanism
Immediate Release
Extended Release

Europe Oral Solid Dosage Pharmaceutical Formulation Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospitals
Clinics
Other

Europe Oral Solid Dosage Pharmaceutical Formulation Market: Players Segment Analysis (Company and Product introduction, Oral Solid Dosage Pharmaceutical Formulation Sales Volume, Revenue, Price and Gross Margin):

AstraZeneca Plc.
Bristol-Myers Squibb Company
Eli Lilly and Company
Gilead Sciences
Merck & Co. Inc.
Novartis AG

Pfizer Inc.
AbbVie Inc.
Boehringer Ingelheim GmbH
Hoffman-La-Roche Ltd.
Johnson & Johnson
Biogen Inc.
Bayer AG
Teva Pharmaceuticals
Amgen Inc.
Takeda Pharmaceutical Company Ltd.
Otsuka Pharmaceutical Co., Ltd.
Shire Plc.
Celgene Corporation
Astellas Pharma Inc.

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 1.1 Definition of Oral Solid Dosage Pharmaceutical Formulation in This Report
- 1.2 Commercial Types of Oral Solid Dosage Pharmaceutical Formulation
 - 1.2.1 By Form
 - 1.2.2 Capsules
 - 1.2.3 Powders
 - 1.2.4 Tablets
 - 1.2.5 By Drug Release Mechanism
 - 1.2.6 Immediate Release
 - 1.2.7 Extended Release
- 1.3 Downstream Application of Oral Solid Dosage Pharmaceutical Formulation
 - 1.3.1 Hospitals
 - 1.3.2 Clinics
 - 1.3.3 Other
- 1.4 Development History of Oral Solid Dosage Pharmaceutical Formulation
- 1.5 Market Status and Trend of Oral Solid Dosage Pharmaceutical Formulation 2013-2023
 - 1.5.1 Europe Oral Solid Dosage Pharmaceutical Formulation Market Status and Trend 2013-2023
 - 1.5.2 Regional Oral Solid Dosage Pharmaceutical Formulation Market Status and Trend 2013-2023

CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Status of Oral Solid Dosage Pharmaceutical Formulation in Europe 2013-2017
- 2.2 Consumption Market of Oral Solid Dosage Pharmaceutical Formulation in Europe by Regions
 - 2.2.1 Consumption Volume of Oral Solid Dosage Pharmaceutical Formulation in Europe by Regions
 - 2.2.2 Revenue of Oral Solid Dosage Pharmaceutical Formulation in Europe by Regions
- 2.3 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Europe by Regions
 - 2.3.1 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Germany

2013-2017

2.3.2 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in United Kingdom 2013-2017

2.3.3 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in France 2013-2017

2.3.4 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Italy 2013-2017

2.3.5 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Spain 2013-2017

2.3.6 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Benelux 2013-2017

2.3.7 Market Analysis of Oral Solid Dosage Pharmaceutical Formulation in Russia 2013-2017

2.4 Market Development Forecast of Oral Solid Dosage Pharmaceutical Formulation in Europe 2018-2023

2.4.1 Market Development Forecast of Oral Solid Dosage Pharmaceutical Formulation in Europe 2018-2023

2.4.2 Market Development Forecast of Oral Solid Dosage Pharmaceutical Formulation by Regions 2018-2023

CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES

3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Oral Solid Dosage Pharmaceutical Formulation in Europe by Types

3.1.2 Revenue of Oral Solid Dosage Pharmaceutical Formulation in Europe by Types

3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

3.3 Market Forecast of Oral Solid Dosage Pharmaceutical Formulation in Europe by Types

CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation in Europe by Downstream Industry
- 4.2 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Major Countries
 - 4.2.1 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Germany
 - 4.2.2 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in United Kingdom
 - 4.2.3 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in France
 - 4.2.4 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Italy
 - 4.2.5 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Spain
 - 4.2.6 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Benelux
 - 4.2.7 Demand Volume of Oral Solid Dosage Pharmaceutical Formulation by Downstream Industry in Russia
- 4.3 Market Forecast of Oral Solid Dosage Pharmaceutical Formulation in Europe by Downstream Industry

CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 5.1 Europe Economy Situation and Trend Overview
- 5.2 Oral Solid Dosage Pharmaceutical Formulation Downstream Industry Situation and Trend Overview

CHAPTER 6 ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE

- 6.1 Sales Volume of Oral Solid Dosage Pharmaceutical Formulation in Europe by Major Players
- 6.2 Revenue of Oral Solid Dosage Pharmaceutical Formulation in Europe by Major Players
- 6.3 Basic Information of Oral Solid Dosage Pharmaceutical Formulation by Major Players
 - 6.3.1 Headquarters Location and Established Time of Oral Solid Dosage

Pharmaceutical Formulation Major Players

6.3.2 Employees and Revenue Level of Oral Solid Dosage Pharmaceutical

Formulation Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

CHAPTER 7 ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

7.1 AstraZeneca Plc.

7.1.1 Company profile

7.1.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.1.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of AstraZeneca Plc.

7.2 Bristol-Myers Squibb Company

7.2.1 Company profile

7.2.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.2.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Company

7.3 Eli Lilly and Company

7.3.1 Company profile

7.3.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.3.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Eli Lilly and Company

7.4 Gilead Sciences

7.4.1 Company profile

7.4.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.4.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Gilead Sciences

7.5 Merck & Co. Inc.

7.5.1 Company profile

7.5.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.5.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Merck & Co. Inc.

7.6 Novartis AG

7.6.1 Company profile

7.6.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.6.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Novartis AG

7.7 Pfizer Inc.

7.7.1 Company profile

7.7.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.7.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Pfizer Inc.

7.8 AbbVie Inc.

7.8.1 Company profile

7.8.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.8.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of AbbVie Inc.

7.9 Boehringer Ingelheim GmbH

7.9.1 Company profile

7.9.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.9.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH

7.10 Hoffman-La-Roche Ltd.

7.10.1 Company profile

7.10.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.10.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Hoffman-La-Roche Ltd.

7.11 Johnson & Johnson

7.11.1 Company profile

7.11.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.11.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Johnson & Johnson

7.12 Biogen Inc.

7.12.1 Company profile

7.12.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.12.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Biogen Inc.

7.13 Bayer AG

7.13.1 Company profile

7.13.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product

7.13.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Bayer AG

7.14 Teva Pharmaceuticals

7.14.1 Company profile

- 7.14.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product
- 7.14.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals
- 7.15 Amgen Inc.
 - 7.15.1 Company profile
 - 7.15.2 Representative Oral Solid Dosage Pharmaceutical Formulation Product
 - 7.15.3 Oral Solid Dosage Pharmaceutical Formulation Sales, Revenue, Price and Gross Margin of Amgen Inc.
- 7.16 Takeda Pharmaceutical Company Ltd.
- 7.17 Otsuka Pharmaceutical Co., Ltd.
- 7.18 Shire Plc.
- 7.19 Celgene Corporation
- 7.20 Astellas Pharma Inc.

CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 8.1 Industry Chain of Oral Solid Dosage Pharmaceutical Formulation
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 9.1 Cost Structure Analysis of Oral Solid Dosage Pharmaceutical Formulation
- 9.2 Raw Materials Cost Analysis of Oral Solid Dosage Pharmaceutical Formulation
- 9.3 Labor Cost Analysis of Oral Solid Dosage Pharmaceutical Formulation
- 9.4 Manufacturing Expenses Analysis of Oral Solid Dosage Pharmaceutical Formulation

CHAPTER 10 MARKETING STATUS ANALYSIS OF ORAL SOLID DOSAGE PHARMACEUTICAL FORMULATION

- 10.1 Marketing Channel
 - 10.1.1 Direct Marketing
 - 10.1.2 Indirect Marketing
 - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
 - 10.2.1 Pricing Strategy
 - 10.2.2 Brand Strategy

- 10.2.3 Target Client
- 10.3 Distributors/Traders List

CHAPTER 11 REPORT CONCLUSION

CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE

- 12.1 Methodology/Research Approach
 - 12.1.1 Research Programs/Design
 - 12.1.2 Market Size Estimation
 - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
 - 12.2.1 Secondary Sources
 - 12.2.2 Primary Sources
- 12.3 Reference

I would like to order

Product name: Oral Solid Dosage Pharmaceutical Formulation-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/O8C502D617FMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/O8C502D617FMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

